This retrospective, real-world cohort study using the ConcertAI Patient360 NSCLC database demonstrated that, from 2016 to 2020, the most common first-line treatment among US patients with locally advanced or metastatic NSCLC who received IO treatment was anti–PD-1/PD-L1 monotherapy, followed by anti–PD-1/PD-L1 agents combined with platinum-based chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.